Who are Tapentadol ER (CG5503)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): dexketoprofen trometamol + tramadol hydrochloride, Ropivacaine + Tramadol, lidocaine+systemic tramadol, CG5503 IR; tapentadol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tapentadol-er-cg5503.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tapentadol ER (CG5503) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tapentadol ER (CG5503) (Tapentadol ER (CG5503)) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mu-opioid receptor agonist and norepinephrine reuptake inhibitor. Area: Pain.

phase 3 mu-opioid receptor agonist and norepinephrine reuptake inhibitor mu-opioid receptor, norepinephrine transporter Pain Small molecule Live · refreshed every 30 min

Target snapshot

Tapentadol ER (CG5503) (Tapentadol ER (CG5503)) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Tapentadol ER is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tapentadol ER (CG5503) TARGET	Tapentadol ER (CG5503)	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	mu-opioid receptor agonist and norepinephrine reuptake inhibitor	mu-opioid receptor, norepinephrine transporter
dexketoprofen trometamol + tramadol hydrochloride	dexketoprofen trometamol + tramadol hydrochloride	Kavaklıdere Umut Hospital	marketed	NSAID + opioid analgesic combination	COX-1/COX-2 (dexketoprofen); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol)
Ropivacaine + Tramadol	Ropivacaine + Tramadol	Aga Khan University	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol)
lidocaine+systemic tramadol	lidocaine+systemic tramadol	Bagcilar Training and Research Hospital	phase 3	Local anesthetic and weak opioid agonist	Mu-opioid receptor, Norepinephrine transporter
CG5503 IR; tapentadol	CG5503 IR; tapentadol	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Mu-opioid receptor agonist and norepinephrine reuptake inhibitor	Mu-opioid receptor (OPRM1); norepinephrine transporter (SLC6A2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mu-opioid receptor agonist and norepinephrine reuptake inhibitor class)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tapentadol ER (CG5503) — Competitive Intelligence Brief. https://druglandscape.com/ci/tapentadol-er-cg5503. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab